SLC7A11 has been described as a key regulator of disulfidptosis, and a therapeutic strategy based on GLUT inhibition-induced disulfidptosis has shown promise in tumor patients with high SLC7A11 levels (23). Here, SLC2A1 is linked to neoplasm.